Tuberculosis

A first-in-class investigational antitubercular agent has shown early bactericidal activity with a low, once-daily oral dose after 14 days of treatment.  The Phase IIa study evaluated GSK’s GSK3036656 in participants with drug-susceptible pulmonary tuberculosis. The company hopes GSK3036656 could be a component of simpler treatment regimens in the future which could help address the TB […]

New research has furthered our understanding of the immune-related factors that drive infection and disease, which will be necessary for an effective tuberculosis (TB) vaccine to be developed. Researchers from the University of Oxford investigated whether previously identified correlates of protection associated with risk of full-blown TB disease could also be associated with risk of […]

The Comprehensive Resistance Prediction for Tuberculosis International Consortium (CRyPTIC) research project has reportedly collected the largest ever global dataset of clinical M. tuberculosis samples from across the world consisting of 15,211 samples from 27 countries on five continents.  Using a new quantitative test for drug resistance and a new approach which identifies all the genetic […]